Manager TitleAgeSince
President 42 -
Corporate Secretary - -
Treasurer 60 -
Director TitleAgeSince
Director/Board Member 42 -
Date Insider Type Main position Quantity % Market Cap. Importance
28/07/20 Tender

General Counsel

15,022 0.2068%
28/07/20 BuyCompany 37,37,360 51.4559%
28/07/20 Tender

Director

15,703 0.2162%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-10.93% - - 1.61Cr
+1.14%+6.61%+40.79%+145.27% 1,28600Cr
+0.79%+3.45%+45.84%+92.04% 69TCr
+0.20%+1.28%+26.97%+114.41% 52TCr
+1.22%+2.14%+42.65%+72.98% 39TCr
+0.55%+0.70%+59.02%+45.79% 36TCr
+1.48%+1.92%+28.59%+63.43% 30TCr
+1.04%+0.53%+4.03%+39.09% 29TCr
-0.30%+1.14%+38.29%+70.56% 25TCr
+0.08%+0.71%+34.44%+123.99% 21TCr
Average +0.67%+2.08%+35.63%+85.28% 48TCr
Weighted average by Cap. +0.74%+3.26%+37.87%+99.80%
Logo Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Employees
-